glp 1 dementia study The EVOKE trials found that semaglutide, the GLP-1 drug behind several popular diabetes and weight loss medications, did not meaningfully slow cognitive decline in people with Alzheimer's disease. Despite these findings, scientists Glucagon-like peptide-1 medicines in neurological

Amount per serving

Releases WADAs 2026 Prohibited List is now in force The World Anti-Doping Agency (WADA) wishes to remind stakeholders that the 2026 List of Prohibited Substances and Methods (List) and the 2026 Monitoring Program are now in force as of today (1 January 2026)

We conducted X-ray diffraction experiments and MD simulations for structural elucidation of the different TRaQ-G adducts to gain mechanistic insight into the varying GSH sensitivities of the molecules

G.AboulthanaW

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Muscle Mass and Strength In a study of 57 men aged 18-50, who were relatively inexperienced in resistance training, the participants were randomly assigned to treatment and placebo groups and underwent baseline measurements before commencing an eight-week resistance training program